Drug-induced pleural diseases

Abstract

The problem of differential diagnosis of pleural diseases involves a large number of pathological conditions causing its damage, which physicians are not aware about. Drug-induced (DI) lesion occupies a special place in the structure of pleural diseases, both due to the relatively low prevalence and due to insufficient awareness of doctors about the presence of such adverse reactions in drugs. At the same time, thanks to modern information about the morphology, physiology and pathophysiology of the pleura and pleural cavities, the diagnosis and treatment of pleural diseases are becoming more and more effective. The article presents the data of modern literature and electronic databases of The Drug-Induced Respiratory Disease Website about DI lesions of the pleura. This review provides information about the main types of DI lesions of the pleura and the scope of drugs that cause these reactions. Ultimately, doctors’ awareness of drug-induced pleural diseases can ensure timely diagnosis of these conditions, correct therapy, and ultimately improve the quality of medical care.

Keywords

pleura / drug-induced pleura injury / pleurisy / pneumothorax / adverse drug reactions

References

[1] Chuchalin AG, Shojhet JaN, Abakumov MM. Pleural diseases. Moscow: Atmosphera; 2018. 276 p. (In Russ.).

[2] Чучалин А.Г., Шойхет Я.Н., Абакумов М.М. Болезни плевры: монография (серий «Монография Российского респираторного общества»). Москва: Атмосфера, 2018. 276 с.

[3] The Drug-Induced Respiratory Disease Website [Internet]. Camus Ph. Available from: http://www.pneumotox.com. Accessed: Nov 27, 2011.

[4] The Drug-Induced Respiratory Disease Website [Internet]. Camus Ph. Режим доступа: http://www.pneumotox.com. Дата обращения 27.11.21.

[5] Decologne N, Kolb M, Margetts PJ, et al. TGF-β1 induces progressive pleural scarring and subpleural fibrosis. Journal of Immunology. 2007;179(9):6043–6051. DOI: 10.4049/jimmunol.179.9.6043

[6] Decologne N., Kolb M., Margetts P.J., et al. TGF-β1 induces progressive pleural scarring and subpleural fibrosis // The Journal of Immunology. 2007. Vol. 179. No. 9. P. 6043–6051. DOI: 10.4049/jimmunol.179.9.6043

[7] Lin CM, Rhiannon JJ, Chan ED. Drug-induced pleural disease. Adverse Drug Reaction Bulletin. 2013;281(1):1083–1086. DOI: 10.1097/FAD.0b013e3283651c4f

[8] Lin C.M., Rhiannon J.J., Chan E.D. Drug-induced pleural disease // Adverse Drug Reaction Bulletin. 2013. Vol. 281, No. 1. P. 1083–1086. DOI: 10.1097/FAD.0b013e3283651c4f

[9] Moschos C, Kalomenidis I. Drug related pleural disease. Pleural Bulletin, Turk Toraks Denergi. 2010;4:8–16.

[10] Moschos C., Kalomenidis I. Drug related pleural disease // Pleural Bulletin, Türk Toraks Denergi. 2010. Vol. 4. P. 8–16.

[11] Allen TC, Suster S. Pathology of the Pleura and Mediastinum. Switzerland: Springer; 2018. 493 p. DOI: 10.1007/978-3-319-66796-6_4299

[12] Allen T.C., Suster S. Pathology of the Pleura and Mediastinum. Switzerland: Springer, 2018. 493 p. DOI: 10.1007/978-3-319-66796-6_4299

[13] Chen JR, Yang YC. Spontaneous pneumothorax after intensive chemotherapy in endometrial cancer: a rare complication. Taiwan J Obstet Gynecol. 2014;53(2):245–247. DOI: 10.1016/j.tjog.2013.09.002

[14] Chen J.R., Yang Y.C. Spontaneous pneumothorax after intensive chemotherapy in endometrial cancer: a rare complication // Taiwan J Obstet Gynecol. 2014. Vol. 53, No. 2. P. 245–247. DOI: 10.1016/j.tjog.2013.09.002

[15] Bazan F, Vollmer I, Gayete A. Chemotherapy-induced secondary pneumothorax. Archivos de Bronconeumologia. 2014;50(1):44. DOI: 10.1016/j.arbres.2013.06.007

[16] Bazan F., Vollmer I., Gayete A. Chemotherapy-induced secondary pneumothorax // Archivos de bronconeumologia. 2014. Vol. 50, No 1. P. 44. DOI: 10.1016/j.arbres.2013.06.007

[17] Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol. 2002;178(2):475–480. DOI: 10.2214/ajr.178.2.1780475

[18] Jung J.I., Choi J.E., Hahn S.T., et al. Radiologic features of all-trans-retinoic acid syndrome // AJR Am J Roentgenol. 2002. Vol. 178, No. 2. P. 475–480. DOI: 10.2214/ajr.178.2.1780475

[19] Amano Y, Tajika K, Mizuki T, et al. All-trans retinoic acid syndrome: chest CT assessment. Eur Radiol. 2001;11(8):1516–1517. DOI: 10.1007/s003300000776

[20] Amano Y., Tajika K., Mizuki T., et al. All-trans retinoic acid syndrome: chest CT assessment // Eur Radiol. 2001. Vol. 11, No. 8. P. 1516–1517. DOI: 10.1007/s003300000776

[21] De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;15;92(8):2712–2718. DOI: 10.1182/blood.V92.8.2712

[22] De Botton S., Dombret H., Sanz M., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group // Blood. 1998. Vol. 92, No. 8. P. 2712–2718. DOI: 10.1182/blood.V92.8.2712

[23] Sharma S, Jagdev S, Coleman RE, et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer. 1999;81(6):1037–1041. DOI: 10.1038/sj.bjc.6690804

[24] Sharma S., Jagdev S., Coleman R.E., et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis // Br J Cancer. 1999. Vol. 81, No. 6. P. 1037–1041. DOI: 10.1038/sj.bjc.6690804

[25] Beynat-Mouterde C, Beltramo G, Lezmi G, et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. European Respiratory Journal. 2014;44(2):523–527. DOI: 10.1183/09031936.00214713

[26] Beynat-Mouterde C., Beltramo G., Lezmi G., et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents // European Respiratory Journal. 2014. Vol. 44, No. 2. P. 523–527. DOI: 10.1183/09031936.00214713

[27] Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide Toxicity. Drugs. 1991;42(5):781–795. DOI: 10.2165/00003495-199142050-00005

[28] Fraiser L.H., Kanekal S., Kehrer J.P. Cyclophosphamide Toxicity // Drugs. 1991. Vol. 42. P. 781–795. DOI: 10.2165/00003495-199142050-00005

[29] Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90(4):E66–E72. DOI: 10.1002/ajh.23938

[30] Cortes J., Mauro M., Steegmann J.L., et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System // Am J Hematol. 2015. Vol. 90, No. 4. P. E66–E72. DOI: 10.1002/ajh.23938

[31] Gennatas S, Stanway SJ, Thomas R, et al. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. BMC Cancer. 2013;13(1):1–4. DOI: 10.1186/1471-2407-13-207

[32] Gennatas S., Stanway S. J., Thomas R., et al. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma // BMC Cancer. 2013. Vol. 13, No. 1. P. 1–4. DOI: 10.1186/1471-2407-13-207

[33] Brunner AM, Costa DB, Heist RS, et al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. Journal of Thoracic Oncology. 2013;8(11):1434–1437. DOI: 10.1097/JTO.0b013e3182a47162

[34] Brunner A.M., Costa D.B., Heist R.S., et al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung // Journal of Thoracic oncology. 2013. Vol. 8, No. 11. P. 1434–1437. DOI: 10.1097/JTO.0b013e3182a47162

[35] Maral S, Bakanay SM, Kucuksahin O, et al. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. J Oncol Pharm Pract. 2020;26(3):738–741. DOI: 10.1177/1078155219863469

[36] Maral S., Bakanay S. M., Kucuksahin O., et al. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib // J Oncol Pharm Pract. 2020. Vol. 26, No. 3. P. 738–741. DOI: 10.1177/1078155219863469

[37] Shen AQ, Wilson NM, Gleason SL, et al. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview. Therapeutic advances in hematology. 2014;5(1):13–17. DOI: 10.1177/2040620713510481

[38] Shen A.Q., Wilson N.M., Gleason S.L., et al. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview // Therapeutic Advances in Hematology. 2014. Vol. 5, No. 1. P. 13–17. DOI: 10.1177/2040620713510481

[39] Nakano K, Motoi N, Tomomatsu J, et al. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis. BMC Cancer. 2016;16(1):1–7. DOI: 10.1186/s12885-016-2786-z

[40] Nakano K., Motoi N., Tomomatsu J., et al. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis // BMC Cancer. 2016. Vol. 16, No. 1. P. 1–7. DOI: 10.1186/s12885-016-2786-z

[41] Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology. 1989;7(1):7–20. DOI: 10.1200/JCO.1989.7.1.7

[42] Lee R.E., Lotze M.T., Skibber J.M., et al. Cardiorespiratory effects of immunotherapy with interleukin-2 // Journal of Clinical Oncology. 1989. Vol. 7, No. 1. P. 7–20. DOI: 10.1200/JCO.1989.7.1.7

[43] Dedov II. Bromokriptinu 50 let. Vestnik Rossiyskoy akademii nauk. 2019;89(11):1137–1142. (In Russ.). DOI: 10.31857/S0869-587389111137-1142

[44] Дедов И.И. Бромокриптину 50 лет // Вестник Российской академии наук. 2019. Т. 89, № 11. С. 1137–1142. DOI: 10.31857/S0869-587389111137-1142

[45] Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement Disorders. 2009;24(1):129–133. DOI: 10.1002/mds.22385

[46] Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists // Movement Disorders. 2009. Vol. 24, No. 1. P. 129–133. DOI: 10.1002/mds.22385

[47] Müller T., Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin Neuropharmacol. 2003;26(3):109–111. DOI: 10.1097/00002826-200305000-00001

[48] Müller T., Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease // Clin Neuropharmacol. 2003. Vol. 26, No. 3. P. 109–111. DOI: 10.1097/00002826-200305000-00001

[49] Champagne S, Coste E, Peyrière H, et al. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases. Ann Pharmacother. 1999;33(10):1050–1054. DOI: 10.1345/aph.18461

[50] Champagne S., Coste E., Peyrière H., et al. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases // Ann Pharmacother. 1999. Vol. 33, No. 10. P. 1050–1054. DOI: 10.1345/aph.18461

[51] Comet R, Domingo C, Such JJ, et al. Pleuropulmonary disease as a side-effect of treatment with bromocriptine. Respir Med. 1998;92(9):1172–1174. DOI: 10.1016/s0954-6111(98)90415-2

[52] Comet R., Domingo C., Such J.J., et al. Pleuropulmonary disease as a side-effect of treatment with bromocriptine // Respir Med. 1998. Vol. 92, No. 9. P. 1172–1174. DOI: 10.1016/s0954-6111(98)90415-2

[53] Hillerdal G, Lee J, Blomkvist A, et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J. 1997;10(12):2711–2715. DOI: 10.1183/09031936.97.10122711

[54] Hillerdal G., Lee J., Blomkvist A., et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos // Eur Respir J. 1997. Vol. 10, No. 12. P. 2711–2715. DOI: 10.1183/09031936.97.10122711

[55] Vergeret J, Barat M, Taytard A, et al. Pleuropulmonary fibrosis and bromocriptine. Sem Hop. 1984;60(11):741–744. (In French.)

[56] Vergeret J., Barat M., Taytard A., et al. Fibrose pleuro-pulmonaire et bromocriptine // Sem Hop. 1984. Vol. 60, No. 11. P. 741–744.

[57] Besser GM, Wass JA. Pleuropulmonary shadows on bromocriptine. Lancet. 1981;1(8215):323. DOI: 10.1016/s0140-6736(81)91927-9

[58] Besser G.M., Wass J.A. Pleuropulmonary shadows on bromocriptine // Lancet. 1981. Vol. 1, No. 8215. P. 323. DOI: 10.1016/s0140-6736(81)91927-9

[59] Tornling G, Unge G, Axelsson G, et al. Pleuropulmonary reactions in patients on bromocriptine treatment. Eur J Respir Dis. 1986;68(1):35–38.

[60] Tornling G., Unge G., Axelsson G., et al. Pleuropulmonary reactions in patients on bromocriptine treatment // Eur J Respir Dis. 1986. Vol. 68, No. 1. P. 35–38.

[61] Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest. 1988;94(5):1034–1036. DOI: 10.1378/chest.94.5.1034

[62] Kinnunen E., Viljanen A. Pleuropulmonary involvement during bromocriptine treatment // Chest. 1988. Vol. 94, No. 5. P. 1034–1036. DOI: 10.1378/chest.94.5.1034.

[63] McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med. 1988;148(10):2231–2236. DOI: 10.1001/archinte.1988.00380100089019

[64] McElvaney N.G., Wilcox P.G., Churg A., et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease // Arch Intern Med. 1988. Vol. 148, No. 10. P. 2231–2236. DOI: 10.1001/archinte.1988.00380100089019

[65] Melmed S, Braunstein GD. Bromocriptine and pleuropulmonary disease. Arch Intern Med. 1989;149(2):258–259. DOI: 10.1001/archinte.1989.00390020008002

[66] Melmed S., Braunstein G.D. Bromocriptine and pleuropulmonary disease // Arch Intern Med. 1989. Vol. 149, No. 2. P. 258–259. DOI: 10.1001/archinte.1989.00390020008002

[67] Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, et al. Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline. Archivos de Bronconeumologia. 2009;45(2):100–102. (In Spanish.) DOI: 10.1016/j.arbres.2008.01.003

[68] Haro-Estarriol M., Sabater-Talaverano G., Rodríguez-Jerez F., et al. Derrame pleural e hipertensión pulmonar en un paciente con enfermedad de Parkinson en tratamiento con cabergoline // Archivos de Bronconeumologia. 2009. Vol. 45, No. 2. P. 100–102. DOI: 10.1016/j.arbres.2008.01.003

[69] Muñoz-Morente A, Garcia-Trujillo L, Soto-Hurtado EJ, et al. Recurrent nerve paralysis and pleural effusion due to cabergoline. Revista de Neurologia. 2008;46(6):382–383. (In Spanish.) DOI: 10.33588/rn.4606.2008116

[70] Muñoz-Morente A., Garcia-Trujillo L., Soto-Hurtado E.J., et al. Parálisis del nervio recurrente y derrame pleural por cabergolina // Revista de Neurologia. 2008. Vol. 46, No. 6. P. 382–383. DOI: 10.33588/rn.4606.2008116

[71] Hawatmeh A, Thawabi M, Jmeian A, et al. Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: A case report and literature review. J Nat Sci Biol Med. 2017;8(1):130–133. DOI: 10.4103/0976-9668.198345

[72] Hawatmeh A., Thawabi M., Jmeian A., et al. Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: A case report and literature review // J Nat Sci Biol Med. 2017. Vol. 8, No. 1. P. 130–133. DOI: 10.4103/0976-9668.198345

[73] Yaşar Bilge NS, Gönüllü E, Kaşifoğlu T, et al. Amiodarone-induced pleural fluid is not always accompanied by a risk factor. Anadolu Kardiyol Derg. 2012;12(3):281–282. DOI: 10.5152/akd.2012.081

[74] Yaşar Bilge N.S., Gönüllü E., Kaşifoğlu T., et al. Amiodarone-induced pleural fluid is not always accompanied by a risk factor // Anadolu Kardiyol Derg. 2012. Vol. 12, No. 3. P. 281–282. DOI: 10.5152/akd.2012.081

[75] Uong V, Nugent K, Alalawi R, et al. Amiodarone-induced loculated pleural effusion: case report and review of the literature. Pharmacotherapy. 2010;30(2):218. DOI: 10.1592/phco.30.2.218

[76] Uong V., Nugent K., Alalawi R., et al. Amiodarone-induced loculated pleural effusion: case report and review of the literature // Pharmacotherapy. 2010. Vol. 30, No. 2. P. 218. DOI: 10.1592/phco.30.2.218

[77] Gonzalez-Rothi RJ, Hannan SE, Hood CI, et al. Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions. Chest. 1987;92(1):179–182. DOI: 10.1378/chest.92.1.179

[78] Gonzalez-Rothi R.J., Hannan S.E., Hood C.I., et al. Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions // Chest. 1987. Vol. 92, No. 1. P. 179–182. DOI: 10.1378/chest.92.1.179

[79] Vernhet H, Bousquet C, Durand G, et al. Reversible amiodarone-induced lung disease: HRCT findings. Eur Radiol. 2001;11(9):1697–1703. DOI: 10.1007/s003300000809

[80] Vernhet H., Bousquet C., Durand G., et al. Reversible amiodarone-induced lung disease: HRCT findings // Eur Radiol. 2001. Vol. 11, No. 9. P. 1697–1703. DOI: 10.1007/s003300000809

[81] Fakhro AM, Ritchie RF, Lown B. Lupus-like syndrome induced by procainamide. Am J Cardiol. 1967;20(3):367–373. DOI: 10.1016/0002-9149(67)90060-4

[82] Fakhro A.M., Ritchie R.F., Lown B. Lupus-like syndrome induced by procainamide // Am J Cardiol. 1967. Vol. 20, No. 3. P. 367–373. DOI: 10.1016/0002-9149(67)90060-4

[83] Stanislav SW, Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine. Annals of Pharmacotherapy. 1999;33(9):1008–1009. DOI: 10.1345/aph.19038

[84] Stanislav S.W., Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine // Annals of Pharmacotherapy. 1999. Vol. 33, No. 9. P. 1008–1009. DOI: 10.1345/aph.19038

[85] Bullington W, Sahn SA, Judson MA. Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature. Am J Med Sci. 2007;333(5):290–292. DOI: 10.1097/MAJ.0b013e31805339ae

[86] Bullington W., Sahn S.A., Judson M.A. Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature // Am J Med Sci. 2007. Vol. 333, No. 5. P. 290–292. DOI: 10.1097/MAJ.0b013e31805339ae

[87] Adoni A, Adatto-Levy R, Mogle P, et al. Postoperative pleural effusion caused by dextran. Int J Gynaecol Obstet. 1980;18(4):243–244. DOI: 10.1002/j.1879-3479.1980.tb00488.x

[88] Adoni A., Adatto-Levy R., Mogle P., et al. Postoperative pleural effusion caused by dextran // Int J Gynaecol Obstet. 1980. Vol. 18, No. 4. P. 243–244. DOI: 10.1002/j.1879-3479.1980.tb00488.x

[89] Roden S, Juvin K, Homasson JP, et al. An uncommon etiology of isolated pleural effusion. The ovarian hyperstimulation syndrome. Chest. 2000;118(1):256–258. DOI: 10.1378/chest.118.1.256

[90] Roden S., Juvin K., Homasson J.P., et al. An uncommon etiology of isolated pleural effusion. The ovarian hyperstimulation syndrome // Chest. 2000. Vol. 118, No. 1. P. 256–258. DOI: 10.1378/chest.118.1.256

[91] Davis JW, Jones LS. Pleural effusion: an uncommon manifestation of nitrofurantoin-induced pulmonary injury. Respiratory Medicine Case Reports. 2016;19:65–67. DOI: 10.1016/j.rmcr.2016.07.009

[92] Davis J.W., Jones L.S. Pleural effusion: an uncommon manifestation of nitrofurantoin-induced pulmonary injury // Respiratory Medicine Case Reports. 2016. Vol. 19. P. 65–67. DOI: 10.1016/j.rmcr.2016.07.009

[93] Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med. 2004;25(1):141–153. DOI: 10.1016/s0272-5231(03)00125-4

[94] Huggins J.T., Sahn S.A. Drug-induced pleural disease // Clin Chest Med. 2004. Vol. 25, No. 1. P. 141–153. DOI: 10.1016/s0272-5231(03)00125-4

[95] Chen YW, Chen YC, Wu CJ, et al. Massive bilateral pleural effusion associated with use of pioglitazone. Clin Ther. 2008;30(8):1485–1489. DOI: 10.1016/j.clinthera.2008.08.003

[96] Chen Y.W., Chen Y.C., Wu C.J., et al. Massive bilateral pleural effusion associated with use of pioglitazone // Clin Ther. 2008. Vol. 30, 8. P. 1485–1489. DOI: 10.1016/j.clinthera.2008.08.003

[97] Tisdale JE, Miller DA. Drug-Induced Diseases: Prevention, Detection and Management. 3rd ed. American Society of Health-Systems Pharmacists. USA: Bethesda; 2018. 1400 p.

[98] Tisdale J.E., Miller D.A. Drug-Induced Diseases: Prevention, Detection and Management. 3rd ed. American Society of Health-Systems Pharmacists. USA: Bethesda, 2018. 1400 p.

[99] Smith 2nd JW. Tolerability and side-effect profile of rhIL-11. Oncology (Williston Park, NY). 2000;14(9 Suppl 8):41–47.

[100] Smith 2nd J.W. Tolerability and side-effect profile of rhIL-11 // Oncology (Williston Park, NY). 2000. Vol. 14, No. 9 Suppl 8. P. 41–47.

[101] Antony VB. Drug-induced pleural disease. Clin Chest Med. 1998;19(2):331–340. DOI: 10.1016/s0272-5231(05)70080-0

[102] Antony V.B. Drug-induced pleural disease // Clin Chest Med. 1998. Vol. 19, No. 2. P. 331–340. DOI: 10.1016/s0272-5231(05)70080-0

[103] Brixey AG, Light RW. Pleural effusions due to dasatinib. Current Opinion in Pulmonary Medicine. 2010;16(4):351–356. DOI: 10.1097/mcp.0b013e328338c486

[104] Brixey A.G., Light R.W. Pleural effusions due to dasatinib // Current Opinion in Pulmonary Medicine. 2010. Vol. 16, No. 4. P. 351–356. DOI: 10.1097/mcp.0b013e328338c486

[105] Jablonskij PK, Petrov AS, Pishhik VG, et al. Spontaneous pneumothorax. Saint Petersburg: St. Petersburg University Publ.; 2013. 42 p. (In Russ.)

[106] Яблонский П.К., Петров А.С., Пищик В.Г., и др. Учебное пособие. Спонтанный пневмоторакс. Санкт-Петербург: Изд-во С.-Петерб. ун-та, 2013. 42 c.

[107] Skol’skaja OJu, Tarasova LN, Vladimirova SG, et al. Prognostic risk factors of ATRA-syndrome in the treatment of acute promyelocytic leukemia. Klinicheskaja laboratornaja diagnostika. 2012;(10):44–47. (In Russ.)

[108] Скольская О.Ю., Тарасова Л.Н., Владимирова С.Г., и др. Прогностические показатели развития ATRA-синдрома при лечении острого промиелоцитарного лейкоза // Клиническая лабораторная диагностика. 2012. № 10. С. 44–47.

[109] Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. DOI: 10.1038/clpt.1981.154

[110] Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions // Clin Pharmacol Ther. 1981. Vol. 30, No. 2. P. 239–245. DOI: 10.1038/clpt.1981.154

[111] Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka. 2020;27(6):113–126. (In Russ.). DOI: 10.18565/pharmateca.2020.6.113-26

[112] Сычев Д.А., Остроумова О.Д., Переверзев А.П., и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике // Фармаконадзор Фарматека. 2020. Vol. 27, No. 6. P. 113–126. DOI: 10.18565/pharmateca.2020.6.113-26

[113] Vesanoid. Eapteka.ru [Internet] Available from: https://www.eapteka.ru/goods/drugs/oncology/vesanoid_khoffmann_lya_rosh/. Accessed: Nov 27, 2011.

[114] Весаноид. Eapteka.ru [интернет] Режим доступа: https://www.eapteka.ru/goods/drugs/oncology/vesanoid_khoffmann_lya_rosh/ Дата обращения: 27.11.21.

[115] Savchenko VG, Parovichnikova EN, Afanas’ev BV, et al. National clinical guidelines for the diagnosis and treatment of acute myeloid leukemia in adults. Gematologija i transfuziologija. 2014;59(S2):64. (In Russ.)

[116] Савченко В.Г., Паровичникова Е.Н., Афанасьев Б.В., и др. Национальные клинические рекомендации по диагностике и лечению острых миелоидных лейкозов взрослых // Гематология и трансфузиология. 2014. Т. 59, № S2. С. 64.

RIGHTS & PERMISSIONS

Ostroumova O.D., Smetneva N.S., De V.A.